Table 4.
Participants Experiencing at Least 1 Adverse Event
| AZD5718 200 mg | ||||||
|---|---|---|---|---|---|---|
| Fasted | Fed | |||||
| Participants With | Rosuvastatin 10 mg (n = 12) | Tablet Plus Rosuvastatin 10 mg (n = 12) | Tablet (n = 12) | Suspension (n = 12) | Tablet (n = 12) | All (n = 12) |
| Any AE, n (%) | 1 (8.3) | 1 (8.3) | 3 (25.0) | 2 (16.7) | 1 (8.3) | 6 (50.0) |
| AEs | ||||||
| Headache, n (%) | 1 (8.3) | 0 | 0 | 1 (8.3)a | 0 | 2 (16.7) |
| Poor‐quality sleep, n (%) | 0 | 0 | 1 (8.3)b | 0 | 0 | 1 (8.3) |
| Nausea, n (%) | 0 | 0 | 0 | 1 (8.3)a | 0 | 1 (8.3) |
| Influenza‐like illness, n (%) | 0 | 0 | 0 | 1 (8.3)b | 0 | 1 (8.3) |
| Nasopharyngitis, n (%) | 0 | 0 | 0 | 0 | 1 (8.3) | 1 (8.3) |
| Musculoskeletal pain, n (%) | 0 | 1 (8.3) | 0 | 0 | 0 | 1 (8.3) |
| Nasal congestion, n (%) | 0 | 0 | 1 (8.3)a | 0 | 0 | 1 (8.3) |
| Oropharyngeal pain, n (%) | 0 | 0 | 1 (8.3)a | 0 | 0 | 1 (8.3) |
| Dry skin, n (%) | 0 | 0 | 1 (8.3) | 0 | 0 | 1 (8.3) |
| Hot flush, n (%) | 0 | 0 | 0 | 1 (8.3)a | 0 | 1 (8.3) |
AE, adverse event.
AEs were coded using Medical Dictionary for Regulatory Activities (MedDRA) version 19.1 vocabulary.
a
Considered possibly related to AZD5718 by the investigator (all other AEs were unrelated).
b
Moderate intensity (all other AEs were mild).